Effects of the insulin sensitizing drug, pioglitazone, and lipopolysaccharide administration on markers of systemic inflammation and clinical parameters in horses

Veterinary Immunology and Immunopathology

Volumn 145, Issue 1-2, 2012, Pages 42-49

  Wearn, Jamie G ^a   Suagee, Jessica K ^b   Crisman, Mark V ^a   Corl, Benjamin A ^b   Hulver, Matthew W ^b   Hodgson, David R ^a   Geor, Ray J ^a,c   McCutcheon, Laura J ^a,c  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Horses; Inflammation; Lipopolysaccharide; Pioglitazone; Pro inflammatory cytokines

Indexed keywords

ACUTE PHASE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORSE DISEASE; INFLAMMATION; NONHUMAN; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; SKELETAL MUSCLE;

ADIPOSE TISSUE; ANIMALS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CHEMOKINE CCL8; FEMALE; HORSE DISEASES; HORSES; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LEPTIN; LIPOPOLYSACCHARIDES; MUSCLE, SKELETAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EQUIDAE;

EID: 84856518743     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2011.10.007     Document Type: Article

References (43)

1. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998, 15:539-553.
2. Bassols J., Ortega F.J., Moreno-Navarrete J.M., Peral B., Ricart W., Fernandez-Real J.M. Study of the proinflammatory role of human differentiated omental adipocytes. J. Cell Biochem. 2009, 107:1107-1117.
3. Berger J.P., Petro A.E., Macnaul K.L., Kelly L.J., Zhang B.B., Richards K., Elbrecht A., Johnson B.A., Zhou G., Doebber T.W., Biswas C., Parikh M., Sharma N., Tanen M.R., Thompson G.M., Ventre J., Adams A.D., Mosley R., Surwit R.S., Moller D.E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. 2003, 17:662-676.
4. Burns T.A., Geor R.J., Mudge M.C., McCutcheon L.J., Hinchcliff K.W., Belknap J.K. Proinflammatory cytokine and chemokine gene expression profiles in subcutaneous and visceral adipose tissue depots of insulin-resistant and insulin-sensitive light breed horses. J. Vet. Intern. Med. 2010, 24:932-939.
5. Cabrero A., Laguna J.C., Vazquez M. Peroxisome proliferator-activated receptors and the control of inflammation. Curr. Drug Targets Inflammat. Allergy 2002, 1:243-248.
6. Chaldakov G.N., Stankulov I.S., Hristova M., Ghenev P.I. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr. Pharm. Des. 2003, 9:1023-1031.
7. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004, 25:4-7.
8. Dandona P., Weinstock R., Thusu K., Abdel-Rahman E., Aljada A., Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 1998, 83:2907-2911.
9. Durham A.E., Rendle D.I., Newton J.E. The effect of metformin on measurements of insulin sensitivity and beta cell response in 18 horses and ponies with insulin resistance. Equine Vet. J. 2008, 40:493-500.
10. Festa A., D'Agostino R., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137.
11. Feve B., Bastard J.P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5:305-311.
12. Firshman A.M., Hustace J.L., Peterson K., Mata J. The Effect of Metformin on Insulin Sensitivity in Horses 2009, American College of Veterinary Internal Medicine, Montreal, Quebec, Canada.
13. Frank N., Geor R.J., Bailey S.R., Durham A.E., Johnson P.J. Equine metabolic syndrome. J. Vet. Intern. Med. 2010, 24:467-475.
14. Frisard M.I., McMillan R.P., Marchand J., Wahlberg K.A., Wu Y., Voelker K.A., Heilbronn L., Haynie K., Muoio B., Li L., Hulver M.W. Toll-like receptor 4 modulates skeletal muscle substrate metabolism. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E988-998.
15. Geor R.J. Metabolic predispositions to laminitis in horses and ponies: obesity, insulin resistance and metabolic syndromes. J. Equine Vet. Sci. 2008, 28:753-759.
16. He J., Usui I., Ishizuka K., Kanatani Y., Hiratani K., Iwata M., Bukhari A., Haruta T., Sasaoka T., Kobayashi M. Interleukin-1alpha inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol. Endocrinol. 2006, 20:114-124.
17. Henneke D.R., Potter G.D., Kreider J.L., Yeates B.F. Relationship between condition score, physical measurements and body fat percentage in mares. Equine Vet. J. 1983, 15:371-372.
18. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995, 95:2409-2415.
19. Hustace J.L., Firshman A.M., Mata J.E. Pharmacokinetics and bioavailability of metformin in horses. Am. J. Vet. Res. 2009, 70:665-668.
20. Jacobsen S., Jensen J.C., Frei S., Jensen A.L., Thoefner M.B. Use of serum amyloid A and other acute phase reactants to monitor the inflammatory response after castration in horses: a field study. Equine Vet. J. 2005, 37:552-556.
21. Jacobsen S., Nielsen J.V., Kjelgaard-Hansen M., Toelboell T., Fjeldborg J., Halling-Thomsen M., Martinussen T., Thoefner M.B. Acute phase response to surgery of varying intensity in horses: a preliminary study. Vet. Surg. 2009, 38:762-769.
22. Johnson P.J. The equine metabolic syndrome peripheral Cushing's syndrome. Vet. Clin. North Am. Equine Pract. 2002, 18:271-293.
23. Kramer D., Shapiro R., Adler A., Bush E., Rondinone C.M. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 2001, 50:1294-1300.
24. Mahajan A., Tabassum R., Chavali S., Dwivedi O.P., Bharadwaj M., Tandon N., Bharadwaj D. High-sensitivity C-reactive protein levels and type 2 diabetes in urban North Indians. J. Clin. Endocrinol. Metab. 2009, 94:2123-2127.
25. Matsuda M., Shimomura I., Sata M., Arita Y., Nishida M., Maeda N., Kumada M., Okamoto Y., Nagaretani H., Nishizawa H., Kishida K., Komuro R., Ouchi N., Kihara S., Nagai R., Funahashi T., Matsuzawa Y. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem. 2002, 277:37487-37491.
26. Meier C.A., Chicheportiche R., Juge-Aubry C.E., Dreyer M.G., Dayer J.M. Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokine 2002, 18:320-328.
27. Mohapatra J., Sharma M., Singh S., Chatterjee A., Swain P., Balaraman R., Patel P.R., Jain M.R. Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice. Pharmacology 2009, 84:203-210.
28. Mozes G., Friedman N., Shainkin-Kestenbaum R. Serum amyloid A: an extremely sensitive marker for intensity of tissue damage in trauma patients and indicator of acute response in various diseases. J. Trauma 1989, 29:71-74.
29. Paltrinieri S., Giordano A., Villani M., Manfrin M., Panzani S., Veronesi M.C. Influence of age and foaling on plasma protein electrophoresis and serum amyloid A and their possible role as markers of equine neonatal septicaemia. Vet. J. 2008, 176:393-396.
30. Pepys M.B., Baltz M.L., Tennent G.A., Kent J., Ousey J., Rossdale P.D. Serum amyloid A protein (SAA) in horses: objective measurement of the acute phase response. Equine Vet. J. 1989, 21:106-109.
31. Rangwala S.M., Lazar M.A. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci. 2004, 25:331-336.
32. Shimizu H., Oh I.S., Tsuchiya T., Ohtani K.I., Okada S., Mori M. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. Diabet. Med. 2006, 23:253-257.
33. Staels B., Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54:2460-2470.
34. Suagee J.K., Burk A.O., Quinn R.W., Hartsock T.G., Douglass L.W. Effects of diet and weight gain on circulating tumour necrosis factor-alpha concentrations in thoroughbred geldings. J. Anim. Physiol. Anim. Nutr. (Berl) 2011, 95:161-170.
35. Thatcher C.D., Pleasant R.S., Geor R.J., Elvinger F., Negrin K.A., Franklin J., Gay L., Werre S.R. Prevalence of obesity in mature horses: an equine body condition study. The American Academy of Veterinary Nutrition 7th Annual Clinical Nutrition and Research Symposium, vol. 6 (Abstract) 2007, (Abstract).
36. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 2006, 6:772-783.
37. Toth F., Frank N., Elliott S.B., Geor R.J., Boston R.C. Effects of an intravenous endotoxin challenge on glucose and insulin dynamics in horses. Am. J. Vet. Res. 2008, 69:82-88.
38. Treiber K., Carter R., Gay L., Williams C., Geor R. Inflammatory and redox status of ponies with a history of pasture-associated laminitis. Vet. Immunol. Immunopathol. 2009, 129:216-220.
39. Vick M.M., Adams A.A., Murphy B.A., Sessions D.R., Horohov D.W., Cook R.F., Shelton B.J., Fitzgerald B.P. Relationships among inflammatory cytokines, obesity, and insulin sensitivity in the horse. J. Anim. Sci. 2007, 85:1144-1155.
40. Vick M.M., Murphy B.A., Sessions D.R., Reedy S.E., Kennedy E.L., Horohov D.W., Cook R.F., Fitzgerald B.P. Effects of systemic inflammation on insulin sensitivity in horses and inflammatory cytokine expression in adipose tissue. Am. J. Vet. Res. 2008, 69:130-139.
41. Vozarova B., Weyer C., Hanson K., Tataranni P.A., Bogardus C., Pratley R.E. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 2001, 9:414-417.
42. Willson T.M., Lambert M.H., Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 2001, 70:341-367.
43. Zhao Y., He X., Shi X., Huang C., Liu J., Zhou S., Heng C.K. Association between serum amyloid A and obesity: a meta-analysis and systematic review. Inflammat. Res. 2010, 59:323-334.